The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?

ABSTRACT: Background: As immunotherapy of oral squamous cell carcinomas (OSCCs), using PD1 inhibitors, is only efficient in a small proportion of patients, additional immune checkpoints need to be identified as potential therapeutic targets. There is evidence that a blockade of CD96 might positively affect the anti-tumor immune response. The aim of this study was to analyze the gene and protein expression of CD96 in the tissue and peripheral blood of OSCC patients compared to healthy controls, while also checking for potential associations with a differential expression to the histomorphological parameters. In addition, possible correlations with the expression of PD1 and PD-L1 as well as the macrophage markers CD68 and CD163 should be tested to obtain further insights into the potential effe

SUBMITTER: Trumet L 

PROVIDER: S-EPMC10093349 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature